Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(6):903–909. doi: 10.1038/bjc.1997.159

Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy.

M P Findlay 1, D Cunningham 1, G Morgan 1, S Clinton 1, A Hardcastle 1, G W Aherne 1
PMCID: PMC2063401  PMID: 9062414

Abstract

The increasing interest in 5-fluorouracil (5-FU) modulation and the development of new antifolates has focused attention in recent studies on the expression of the target enzyme thymidylate synthase (TS) as a determinant of drug sensitivity and resistance. Resistance to TS-directed drugs has been shown to occur in vitro and in vivo with increased expression of the enzyme (determined by enzymatic assays as well as protein and gene expression assays). Several studies have evaluated the role of TS as a prognostic indicator of clinical response to chemotherapy containing TS-directed drugs. We have used a polyclonal antibody to recombinant human TS to establish a silver-enhanced immunogold staining method to localize TS in human tumours. Human tumour cell lines with acquired resistance to TS inhibitors owing to increased levels of TS were used to confirm the specificity of immunostaining. Stained sections were evaluated by image analysis. Immunostaining in tumour sections was greatly reduced (>80%) by preabsorption of the antiserum with recombinant TS. The method was used to determine the extent of TS immunostaining in 134 primary human colorectal tumours. The results were then compared with the clinical outcome and response to chemotherapy for the treatment of subsequent metastatic disease. A wide range (approximately 100-fold) of TS immunostaining was observed in these primary tumour sections. Normal mucosal tissue levels were 5-10 times lower than those observed in the adjacent tumour tissue. The values for TS immunostaining did not correlate with clinical endpoints, such as time from diagnosis to relapse, response to chemotherapy for disseminated disease, nor with Dukes' staging. This lack of correlation may be because this group of patients was selected on the basis of their need for palliative chemotherapy and did not include patients who were cured of their disease. Also, primary tumour TS expression may not give a good indication of the TS expression in metastatic lesions. The prognostic significance of TS protein expression in primary and metastatic lesions requires further evaluation.

Full text

PDF
903

Images in this article

905Figure 1
on p.905
905Figure 2
on p.905

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beck A., Etienne M. C., Chéradame S., Fischel J. L., Formento P., Renée N., Milano G. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer. 1994;30A(10):1517–1522. doi: 10.1016/0959-8049(94)00216-r. [DOI] [PubMed] [Google Scholar]
  2. Berger S. H., Jenh C. H., Johnson L. F., Berger F. G. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol Pharmacol. 1985 Nov;28(5):461–467. [PubMed] [Google Scholar]
  3. Cadman E., Heimer R. Levels of thymidylate synthetase during normal culture growth of L1210 cells. Cancer Res. 1986 Mar;46(3):1195–1198. [PubMed] [Google Scholar]
  4. Chu E., Zinn S., Boarman D., Allegra C. J. Interaction of gamma interferon and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res. 1990 Sep 15;50(18):5834–5840. [PubMed] [Google Scholar]
  5. Clark J. L., Berger S. H., Mittelman A., Berger F. G. Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy. Cancer Treat Rep. 1987 Mar;71(3):261–265. [PubMed] [Google Scholar]
  6. Etienne M. C., Chéradame S., Fischel J. L., Formento P., Dassonville O., Renée N., Schneider M., Thyss A., Demard F., Milano G. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol. 1995 Jul;13(7):1663–1670. doi: 10.1200/JCO.1995.13.7.1663. [DOI] [PubMed] [Google Scholar]
  7. Fisher B., Wolmark N., Rockette H., Redmond C., Deutsch M., Wickerham D. L., Fisher E. R., Caplan R., Jones J., Lerner H. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst. 1988 Mar 2;80(1):21–29. doi: 10.1093/jnci/80.1.21. [DOI] [PubMed] [Google Scholar]
  8. Freemantle S. J., Jackman A. L., Kelland L. R., Calvert A. H., Lunec J. Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694. Br J Cancer. 1995 May;71(5):925–930. doi: 10.1038/bjc.1995.179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Glimelius B., Hoffman K., Haglund U., Nyrén O., Sjödén P. O. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol. 1994 Feb;5(2):189–190. doi: 10.1093/oxfordjournals.annonc.a058778. [DOI] [PubMed] [Google Scholar]
  10. Hill M., Norman A., Cunningham D., Findlay M., Nicolson V., Hill A., Iveson A., Evans C., Joffe J., Nicolson M. Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol. 1995 Jun;13(6):1297–1302. doi: 10.1200/JCO.1995.13.6.1297. [DOI] [PubMed] [Google Scholar]
  11. Holgate C. S., Jackson P., Lauder I., Cowen P. N., Bird C. C. Surface membrane staining of immunoglobulins in paraffin sections of non-Hodgkin's lymphomas using immunogold-silver staining technique. J Clin Pathol. 1983 Jul;36(7):742–746. doi: 10.1136/jcp.36.7.742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Horikoshi T., Danenberg K. D., Stadlbauer T. H., Volkenandt M., Shea L. C., Aigner K., Gustavsson B., Leichman L., Frösing R., Ray M. Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res. 1992 Jan 1;52(1):108–116. [PubMed] [Google Scholar]
  13. Jackman A. L., Calvert A. H. Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol. 1995 Nov;6(9):871–881. doi: 10.1093/oxfordjournals.annonc.a059353. [DOI] [PubMed] [Google Scholar]
  14. Jackman A. L., Farrugia D. C., Gibson W., Kimbell R., Harrap K. R., Stephens T. C., Azab M., Boyle F. T. ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1277–1282. doi: 10.1016/0959-8049(95)00166-g. [DOI] [PubMed] [Google Scholar]
  15. Jackman A. L., Taylor G. A., Gibson W., Kimbell R., Brown M., Calvert A. H., Judson I. R., Hughes L. R. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res. 1991 Oct 15;51(20):5579–5586. [PubMed] [Google Scholar]
  16. Jastreboff M. M., Todd M. B., Malech H. L., Bertino J. R. Isolation and functional effects of monoclonal antibodies binding to thymidylate synthase. Biochemistry. 1985 Jan 29;24(3):587–592. doi: 10.1021/bi00324a007. [DOI] [PubMed] [Google Scholar]
  17. Johnston P. G., Drake J. C., Steinberg S. M., Allegra C. J. Quantitation of thymidylate synthase in human tumors using an ultrasensitive enzyme-linked immunoassay. Biochem Pharmacol. 1993 Jun 22;45(12):2483–2486. doi: 10.1016/0006-2952(93)90230-t. [DOI] [PubMed] [Google Scholar]
  18. Johnston P. G., Drake J. C., Trepel J., Allegra C. J. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res. 1992 Aug 15;52(16):4306–4312. [PubMed] [Google Scholar]
  19. Johnston P. G., Fisher E. R., Rockette H. E., Fisher B., Wolmark N., Drake J. C., Chabner B. A., Allegra C. J. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol. 1994 Dec;12(12):2640–2647. doi: 10.1200/JCO.1994.12.12.2640. [DOI] [PubMed] [Google Scholar]
  20. Johnston P. G., Lenz H. J., Leichman C. G., Danenberg K. D., Allegra C. J., Danenberg P. V., Leichman L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 1995 Apr 1;55(7):1407–1412. [PubMed] [Google Scholar]
  21. Johnston P. G., Liang C. M., Henry S., Chabner B. A., Allegra C. J. Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. Cancer Res. 1991 Dec 15;51(24):6668–6676. [PubMed] [Google Scholar]
  22. Jones M., Siracky J., Kelland L. R., Harrap K. R. Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts. Br J Cancer. 1993 Jan;67(1):24–29. doi: 10.1038/bjc.1993.5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Leichman L., Lenz H. J., Leichman C. G., Groshen S., Danenberg K., Baranda J., Spears C. P., Boswell W., Silberman H., Ortega A. Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1306–1310. doi: 10.1016/0959-8049(95)00326-e. [DOI] [PubMed] [Google Scholar]
  24. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  25. Mulder N. H., Timmer-Bosscha H., Meersma G. J., Verschueren R. C. Thymidylate synthase levels in tumor biopsies from patients with colorectal cancer. Anticancer Res. 1994 Nov-Dec;14(6B):2677–2680. [PubMed] [Google Scholar]
  26. Navalgund L. G., Rossana C., Muench A. J., Johnson L. F. Cell cycle regulation of thymidylate synthetase gene expression in cultured mouse fibroblasts. J Biol Chem. 1980 Aug 10;255(15):7386–7390. [PubMed] [Google Scholar]
  27. Peters G. J., van Groeningen C. J., Laurensse E. J., Pinedo H. M. Thymidylate synthase from untreated human colorectal cancer and colonic mucosa: enzyme activity and inhibition by 5-fluoro-2'-deoxy-uridine-5'-monophosphate. Eur J Cancer. 1991;27(3):263–267. doi: 10.1016/0277-5379(91)90512-c. [DOI] [PubMed] [Google Scholar]
  28. Peters G. J., van der Wilt C. L., van Groeningen C. J. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase. Eur J Cancer. 1994;30A(10):1408–1411. doi: 10.1016/0959-8049(94)00218-t. [DOI] [PubMed] [Google Scholar]
  29. Peters G. J., van der Wilt C. L., van Triest B., Codacci-Pisanelli G., Johnston P. G., van Groeningen C. J., Pinedo H. M. Thymidylate synthase and drug resistance. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1299–1305. doi: 10.1016/0959-8049(95)00172-f. [DOI] [PubMed] [Google Scholar]
  30. Sakamoto S., Ebuchi M., Iwama T. Relative activities of thymidylate synthetase and thymidine kinase in human mammary tumours. Anticancer Res. 1993 Jan-Feb;13(1):205–207. [PubMed] [Google Scholar]
  31. Sanguedolce R., Brumarescu I., Dardanoni G., Grassadonia A., Vultaggio G., Rausa L. Thymidylate synthase level and DNA-ploidy pattern as possible prognostic factors in human colorectal cancer: a preliminary study. Anticancer Res. 1995 May-Jun;15(3):901–906. [PubMed] [Google Scholar]
  32. Sotos G. A., Grogan L., Allegra C. J. Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treat Rev. 1994 Jan;20(1):11–49. doi: 10.1016/0305-7372(94)90009-4. [DOI] [PubMed] [Google Scholar]
  33. Specht L., Carde P., Mauch P., Magrini S. M., Santarelli M. T. Radiotherapy versus combined modality in early stages. Ann Oncol. 1992 Sep;3 (Suppl 4):77–81. doi: 10.1093/annonc/3.suppl_4.s77. [DOI] [PubMed] [Google Scholar]
  34. Suzuki M., Ohwada M., Tamada T., Tsuru S. Thymidylate synthase activity as a prognostic factor in ovarian cancer. Oncology. 1994 Jul-Aug;51(4):334–338. doi: 10.1159/000227360. [DOI] [PubMed] [Google Scholar]
  35. Swain S. M., Lippman M. E., Egan E. F., Drake J. C., Steinberg S. M., Allegra C. J. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol. 1989 Jul;7(7):890–899. doi: 10.1200/JCO.1989.7.7.890. [DOI] [PubMed] [Google Scholar]
  36. Van der Wilt C. L., Pinedo H. M., Smid K., Peters G. J. Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. Cancer Res. 1992 Sep 15;52(18):4922–4928. [PubMed] [Google Scholar]
  37. Van der Wilt C. L., Smid K., Aherne G. W., Pinedo H. M., Peters G. J. Evaluation of immunohistochemical staining and activity of thymidylate synthase in cell lines. Adv Exp Med Biol. 1993;338:605–608. doi: 10.1007/978-1-4615-2960-6_124. [DOI] [PubMed] [Google Scholar]
  38. Volm M., Mattern J. Elevated expression of thymidylate synthase in doxorubicin resistant human non small cell lung carcinomas. Anticancer Res. 1992 Nov-Dec;12(6B):2293–2296. [PubMed] [Google Scholar]
  39. Volm M., Zintl F., Sauerbrey A. Thymidylate synthase in childhood acute non-lymphoblastic leukemia. Anticancer Res. 1994 May-Jun;14(3B):1271–1275. [PubMed] [Google Scholar]
  40. Zeng Z. S., Sarkis A. S., Zhang Z. F., Klimstra D. S., Charytonowicz E., Guillem J. G., Cordon-Cardo C., Cohen A. M. p53 nuclear overexpression: an independent predictor of survival in lymph node--positive colorectal cancer patients. J Clin Oncol. 1994 Oct;12(10):2043–2050. doi: 10.1200/JCO.1994.12.10.2043. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES